S-Space

Browse

Author

Jump to a point in the index

Or type in a year

Sort by
In order
Results/Page
Authors/record

Showing results 121 to 180 of 278

Issue Date	Title / Author(s) / Citation	File
2016-02	Clinical application of genomic profiling to find druggable targets for adolescent and young adult (AYA) cancer patients with metastasis Cha, Soojin; Lee, Jeongeun; Shin, Jong-Yeon; Kim, Ji-Yeon; Sim, Sung Hoon; Keam, Bhumsuk; Kim, Tae Min; Kim, Dong-Wan; Heo, Dae Seog; Lee, Se-Hoon; Kim, Jong-Il BMC Cancer, Vol.16, p. 170	view file DOI
2016-02	Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02) Lee, Ji Yun; Xu Qing; Wei Xiumin; Bai Yali; Chi, Sangah; Bak, So Hyeon; Lee, Ho Yun; Sun, Jong-Mu; Lee, Se-Hoon; Ahn, Jin Seok; Cho, Eun Kyung; Kim, Dong-Wan; Kim, Hye Ryun; Min, Young Joo; Jung, Sin-Ho; Park, Keunchil; Mao Mao; Ahn, Myung-Ju Oncotarget, Vol.7 No.6, pp.6984-6993	view file DOI
2016-02	Effect of induction chemotherapy on survival in locally advanced head and neck squamous cell carcinoma treated with concurrent chemoradiotherapy: Single center experience Ock, Chan-Young; Keam, Bhumsuk; Lim, Yoojoo; Kim, Tae Min; Lee, Se-Hoon; Kwon, Seong Keun; Hah, J. Hun; Kwon, Tack-Kyun; Kim, Dong-Wan; Wu, Hong-Gyun; Sung, Myung-Whun; Heo, Dae Seog Head and Neck, Vol.38 No.2, pp.277-284	DOI
2016-03	Pretreatment albumin-to-globulin ratio as a predictive marker for tyrosine kinase inhibitor in non-small cell lung cancer Park, Sehhoon; Park, Seongyeol; Lee, Se-Hoon; Suh, Beomseok; Ock, Chan-Young; Keam, Bhumsuk; Kim, Tae Min; Kim, Dong-Wan; Kim, Young Whan; Heo, Dae Seog Cancer Biomarkers, Vol.16 No.3, pp.425-433	DOI
2016-03	Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial Schuler, M.; Yang, J. C. -H.; Park, K.; Kim, J. -H.; Bennouna, J.; Chen, Y. -M.; Chouaid, C.; De Marinis, F.; Feng, J. -F.; Grossi, F.; Kim, D. -W.; Liu, X.; Lu, S.; Strausz, J.; Vinnyk, Y.; Wiewrodt, R.; Zhou, C.; Wang, B.; Chand, V. K.; Planchard, D. Annals of Oncology, Vol.27 No.3, pp.417-423	DOI
2016-03	Pretreatment neutrophil-lymphocyte ratio is not a significant prognostic factor in epidermal growth factor receptor-mutant non-small cell lung cancer patients treated with tyrosine kinase inhibitors Sim, Sung Hoon; Beom, Seung-Hoon; Ahn, Yong-Oon; Keam, Bhumsuk; Kim, Tae Min; Lee, Se-Hoon; Kim, Dong-Wan; Heo, Dae Seog Thoracic Cancer, Vol.7 No.2, pp.161-166	view file DOI
2016-03	EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1 alpha and STAT3 Koh, Jaemoon; Jang, Ji-Young; Keam, Bhumsuk; Kim, Sehui; Kim, Moon-Young; Go, Heounjeong; Kim, Tae Min; Kim, Dong-Wan; Kim, Chul-Woo; Jeon, Yoon Kyung; Chung, Doo Hyun OncoImmunology, Vol.5 No.3, p. e1108514	DOI
2016-03	Alectinib in crizotinib-refractory alk-rearranged non-small-cell lung cancer: A phase II global study Ou, Sai-Hong Ignatius; Ahn, Jin Seok; De Petris, Luigi; Govindan, Ramaswamy; Yang, James Chih-Hsin; Hughes, Brett; Lena, Herve; Moro-Sibilot, Denis; Bearz, Alessandra; Ramirez, Santiago Viteri; Mekhail, Tarek; Spira, Alexander; Bordogna, Walter; Balas, Bogdana; Morcos, Peter N.; Monnet, Annabelle; Zeaiter, Ali; Kim, Dong-Wan Journal of Clinical Oncology, Vol.34 No.7, pp.661-668	DOI
2016-03	A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806) Lim, Sun Min; Cho, Byoung Chul; Kim, Sang-We; Kang, Seok Yun; Heo, Dae Seog; Kim, Heung Tae; Lee, Dae Ho; Kim, Dong-Wan; Jung, Minkyu; Choi, Jin-Hyuk; Shim, Hyo Sup; Choi, Jong Rak; Kim, Joo-Hang Lung Cancer, Vol.93, pp.1-8	DOI
2016-03	PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma Ock, Chan-Young; Kim, Sehui; Keam, Bhumsuk; Kim, Miso; Kim, Tae Min; Kim, Jin-Ho; Jeon, Yoon Kyung; Lee, Ju-Seog; Kwon, Seong Keun; Hah, J. Hun; Kwon, Tack-Kyun; Kim, Dong-Wan; Wu, Hong-Gyun; Sung, Myung-Whun; Heo, Dae Seog Oncotarget, Vol.7 No.13, pp.15901-15914	view file DOI
2016-03	Phase I study of random healthy donor-derived allogeneic natural killer cell therapy in patients with malignant lymphoma or advanced solid tumors Yang, Yaewon; Lim, Okjae; Kim, Tae Min; Ahn, Yong-Oon; Choi, Hana; Chung, Hyejin; Min, Bokyung; Her, Jung Hyun; Cho, Sung Yoo; Keam, Bhumsuk; Lee, Se-Hoon; Kim, Dong-Wan; Hwang, Yu Kyeong; Heo, Dae Seog Cancer immunology research, Vol.4 No.3, pp.215-224	DOI
2016-04	Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial Kim, Dong-Wan; Mehra, Ranee; Tan, Daniel S. W.; Felip, Enriqueta; Chow, Laura Q. M.; Camidge, D. Ross; Vansteenkiste, Johan; Sharma, Sunil; De Pas, Tommaso; Riely, Gregory J.; Solomon, Benjamin J.; Wolf, Juergen; Thomas, Michael; Schuler, Martin; Liu, Geoffrey; Santoro, Armando; Sutradhar, Santosh; Li, Siyu; Szczudlo, Tomasz; Yovine, Alejandro; Shaw, Alice T. The Lancet Oncology, Vol.17 No.4, pp.452-463	DOI
2016-04	Identification of genomic mutations associated with clinical outcomes of induction chemotherapy in patients with head and neck squamous cell carcinoma Ock, Chan-Young; Son, Bongjun; Keam, Bhumsuk; Lee, Seung-Youn; Moon, Jaewoo; Kwak, Hwanjong; Kim, Sehui; Kim, Tae Min; Jeon, Yoon Kyung; Kwon, Seong Keun; Hah, J. Hun; Lee, Se-Hoon; Kwon, Tack-Kyun; Kim, Dong-Wan; Wu, Hong-Gyun; Sung, Myung-Whun; Heo, Dae Seog Journal of Cancer Research and Clinical Oncology, Vol.142 No.4, pp.873-883	DOI
2016-04	Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial Herbst, Roy S.; Baas, Paul; Kim, Dong-Wan; Felip, Enriqueta; Perez-Gracia, Jose L.; Han, Ji-Youn; Molina, Julian; Kim, Joo-Hang; Arvis, Catherine Dubos; Ahn, Myung-Ju; Majem, Margarita; Fidler, Mary J.; de Castro, Gilberto, Jr.; Garrido, Marcelo; Lubiniecki, Gregory M.; Shentu, Yue; Im, Ellie; Dolled-Filhart, Marisa; Garon, Edward B. The Lancet, Vol.387 No.10027, pp.1540-1550	DOI
2016-04	Tolerability and Outcomes of First-Line Pemetrexed-Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in Korean Patients with Advanced Nonsquamous Non-small Cell Lung Cancer: A Post Hoc Descriptive Subgroup Analysis of a Randomized, Phase 3 Trial Kang, Jin Hyoung; Ahn, Myung-Ju; Kim, Dong-Wan; Cho, Eun Kyung; Kim, Joo-Hang; Shin, Sang Won; Wang, Xin; Kim, Jong Seok; Orlando, Mauro; Park, Keunchil Cancer Research and Treatment, Vol.48 No.2, pp.458-464	view file DOI
2016-04	Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies Planchard, David; Brown, Kathryn H.; Kim, Dong-Wan; Kim, Sang-We; Ohe, Yuichiro; Felip, Enriqueta; Leese, Philip; Cantarini, Mireille; Vishwanathan, Karthick; Jaenne, Pasi A.; Ranson, Malcolm; Dickinson, Paul A. Cancer Chemotherapy and Pharmacology, Vol.77 No.4, pp.767-776	DOI
2016-05	Induction chemotherapy in head and neck squamous cell carcinoma of the paranasal sinus and nasal cavity: A role in organ preservation Ock, Chan-Young; Keam, Bhumsuk; Kim, Tae Min; Han, Doo Hee; Won, Tae-Bin; Lee, Se-Hoon; Hah, J. Hun; Kwon, Tack-Kyun; Kim, Dong-Wan; Kim, Dong-Young; Rhee, Chae-Seo; Wu, Hong-Gyun; Sung, Myung-Whun; Heo, Dae Seog The Korean Journal of Internal Medicine, Vol.31 No.3, pp.570-578	view file DOI
2016-05	Pan-cancer immunogenomic perspective on the tumor microenvironment based on PD-L1 and CD8 T-cell infiltration Ock, Chan-Young; Keam, Bhumsuk; Kim, Sehui; Lee, Ju-Seog; Kim, Miso; Kim, Tae Min; Jeon, Yoon Kyung; Kim, Dong-Wan; Chung, Doo Hyun; Heo, Dae Seog Clinical Cancer Research, Vol.22 No.9, pp.2261-2270	DOI
2016-05	Graves patient with thymic expression of thyrotropin receptors and dynamic changes in thymic hyperplasia proportional to graves disease activity Song, Young Shin; Won, Jae-Kyung; Kim, Mi Jeong; Lee, Ji Hyun; Kim, Dong-Wan; Chung, June-Key; Park, Do Joon; Park, Young Joo Yonsei Medical Journal, Vol.57 No.3, pp.795-798	view file DOI
2016-05	Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial Park, Keunchil; Tan, Eng-Huat; O'Byrne, Ken; Zhang, Li; Boyer, Michael; Mok, Tony; Hirsh, Vera; Yang, James Chih-Hsin; Lee, Ki Hyeong; Lu, Shun; Shi, Yuankai; Kim, Sang-We; Laskin, Janessa; Kim, Dong-Wan; Arvis, Catherine Dubos; Kolbeck, Arvis Karl; Laurie, Scott A.; Tsai, Chun-Ming; Shahidi, Mehdi; Kim, Miyoung; Massey, Dan; Zazulina, Victoria; Paz-Ares, Luis The Lancet Oncology, Vol.17 No.5, pp.577-589	DOI
2016-07	Serum Neuron-Specific Enolase Levels Predict the Efficacy of First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations Suh, Koung Jin; Keam, Bhumsuk; Kim, Miso; Park, Young Sik; Kim, Tae Min; Jeon, Yoon Kyung; Kim, Dong-Wan; Chung, Doo Hyun; Kim, Young Whan; Heo, Dae Seog Clinical Lung Cancer, Vol.17 No.4, pp.245-252.e1	DOI
2016-07	Change in PD-L1 Expression After Acquiring Resistance to Gefitinib in EGFR-Mutant Non-Small-Cell Lung Cancer Han, Jae Joon; Kim, Dong-Wan; Koh, Jaemoon; Keam, Bhumsuk; Kim, Tae Min; Jeon, Yoon Kyung; Lee, Se-Hoon; Chung, Doo Hyun; Heo, Dae Seog Clinical Lung Cancer, Vol.17 No.4, pp.263-270	DOI
2016-07	The effect of induction chemotherapy using docetaxel, cisplatin, and fluorouracil on survival in locally advanced head and neck squamous cell carcinoma: A meta-analysis Kim, Ryul; Hahn, Seokyung; Shin, Junghoon; Ock, Chan-Young; Kim, Miso; Keam, Bhumsuk; Kim, Tae Min; Kim, Dong-Wan; Heo, Dae Seog Cancer Research and Treatment, Vol.48 No.3, pp.907-916	view file DOI
2016-08	Intracranial efficacy of crizotinib versus chemotherapy in patients with advanced ALK-positive non-small-cell lung cancer: Results from PROFILE 1014 Solomon, Benjamin J.; Cappuzzo, Federico; Felip, Enriqueta; Blackhall, Fiona H.; Costa, Daniel B.; Kim, Dong-Wan; Nakagawa, Kazuhiko; Wu, Yi-Long; Mekhail, Tarek; Paolini, Jolanda; Tursi, Jennifer; Usari, Tiziana; Wilner, Keith D.; Selaru, Paulina; Mok, Tony S. K. Journal of Clinical Oncology, Vol.34 No.24, pp.2858-2865	DOI
2016-10	Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity Ballard, Peter; Yates, James W. T.; Yang, Zhenfan; Kim, Dong-Wan; Yang, James Chih-Hsin; Cantarini, Mireille; Pickup, Kathryn; Jordan, Angela; Hickey, Mike; Grist, Matthew; Box, Matthew; Johnstrom, Peter; Varnas, Katarina; Malmquist, Jonas; Thress, Kenneth S.; Janne, Pasi A.; Cross, Darren Clinical Cancer Research, Vol.22 No.20, pp.5130-5140	DOI
2016-10	Programmed death ligand-1 expression and its prognostic role in esophageal squamous cell carcinoma Kim, Ryul; Keam, Bhumsuk; Kwon, Dohee; Ock, Chan-Young; Kim, Miso; Kim, Tae Min; Kim, Hak Jae; Jeon, Yoon Kyung; Park, In Kyu; Kang, Chang Hyun; Kim, Dong-Wan; Kim, Young Tae; Heo, Dae Seog World Journal of Gastroenterology, Vol.22 No.37, pp.8389-8397	view file DOI
2016-11	Nutritional status in the era of target therapy: poor nutrition is a prognostic factor in non-small cell lung cancer with activating epidermal growth factor receptor mutations Park, Sehhoon; Park, Seongyeol; Lee, Se-Hoon; Suh, Beomseok; Keam, Bhumsuk; Kim, Tae Min; Kim, Dong-Wan; Kim, Young Whan; Heo, Dae Seog The Korean Journal of Internal Medicine, Vol.31 No.6, pp.1140-1149	view file DOI
2016-12	Pooled analysis of CNS response to alectinib in two studies of pretreated patients with ALK-positive non-small-cell lung cancer Gadgeel, Shirish M.; Shaw, Alice T.; Govindan, Ramaswamy; Gandhi, Leena; Socinski, Mark A.; Camidge, D. Ross; De Petris, Luigi; Kim, Dong-Wan; Chiappori, Alberto; Moro-Sibilot, Denis L.; Duruisseaux, Michael; Crino, Lucio; De Pas, Tommaso; Dansin, Eric; Tessmer, Antje; Yang, James Chih-Hsin; Han, Ji-Youn; Bordogna, Walter; Golding, Sophie; Zeaiter, Ali; Ou, Sai-Hong Ignatius Journal of Clinical Oncology, Vol.34 No.34, pp.4079-4085	DOI
2016-12	AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases Yang, Zhenfan; Guo, Qiuli; Wang, Yingchun; Chen, Kan; Zhang, Lin; Cheng, Ziqiang; Xu, Yanping; Yin, Xiaolu; Bai, Yu; Rabbie, Sarit; Kim, Dong-Wan; Ahn, Myung-Ju; Yang, James Chih-Hsin; Zhang, Xiaolin Science Translational Medicine, Vol.8 No.368, p. 368ra172	DOI
2017-01	Post-bevacizumab clinical outcomes and the impact of early discontinuation of bevacizumab in patients with recurrent malignant glioma Cha, Yongjun; Kim, Yu Jung; Lee, Se-Hoon; Kim, Tae-Min; Choi, Seung Hong; Kim, Dong-Wan; Park, Chul-Kee; Kim, Il Han; Kim, Jee Hyun; Kim, Eunhee; Choi, Byungse; Kim, Chae-Yong; Kim, In Ah; Heo, Dae Seog Cancer Research and Treatment, Vol.49 No.1, pp.129-140	view file DOI
2017-01	Clinical outcomes of stereotactic ablative radiotherapy in patients with pulmonary metastasis Jang, Bum-Sup; Kim, Hak Jae; Kim, Byoung Hyuck; Kim, Dong-Wan; Kim, Young Tae; Kim, Young Whan; Jang, Myoung-Jin; Wu, Hong-Gyun Japanese Journal of Clinical Oncology, Vol.47 No.1, pp.61-66	DOI
2017-02	Acquired resistance mechanisms to capmatinib, a MET inhibitor in MET-amplified non-small cell lung cancer cells Kim Seulki	view file
2017-02	Alterations in PD-L1 expression associated with acquisition of resistance to ALK inhibitors in Anaplastic lymphoma kinase-rearranged lung cancer 김수정	view file
2017-02	Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial Lee, Se-Hoon; Lee, J. -K.; Ahn, M. -J.; Kim, D. -W.; Sun, J. -M.; Keam, B.; Kim, T. M.; Heo, D. S.; Ahn, J. S.; Choi, Y. -L.; Min, H. -S.; Jeon, Y. K.; Park, K. Annals of Oncology, Vol.28 No.2, pp.292-297	DOI
2017-02	Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial Paz-Ares, L.; Tan, E. -H.; O'Byrne, K.; Zhang, L.; Hirsh, V.; Boyer, M.; Yang, J. C. -H.; Mok, T.; Lee, K. H.; Lu, S.; Shi, Y.; Lee, D. H.; Laskin, J.; Kim, D. -W.; Laurie, S. A.; Kolbeck, K.; Fan, J.; Dodd, N.; Marten, A.; Park, K. Annals of Oncology, Vol.28 No.2, pp.270-277	DOI
2017-02	Proportion and clinical features of never-smokers with non-small cell lung cancer Cho, Jaeyoung; Choi, Sun Mi; Lee, Jinwoo; Lee, Chang-Hoon; Lee, Sang-Min; Kim, Dong-Wan; Yim, Jae-Joon; Kim, Young Tae; Yoo, Chul-Gyu; Kim, Young Whan; Han, Sung Koo; Park, Young Sik Chinese Journal of Cancer, Vol.36 No.1, p. 20	view file DOI
2017-02	A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01) Kim, Hye Ryun; Jang, Joung Soon; Sun, Jong-Mu; Ahn, Myung-Ju; Kim, Dong-Wan; Jung, Inkyung; Lee, Ki Hyeong; Kim, Joo-Hang; Lee, Dae Ho; Kim, Sang-We; Cho, Byoung Chul Oncotarget, Vol.8 No.9, pp.15943-15951	view file DOI
2017-02	Evaluation of the effects and adverse drug reactions of low-dose dexamethasone premedication with weekly docetaxel Kang, Rae Young; Yoo, Kyung Sook; Han, Hyeon Ju; Lee, Ju-Yeun; Lee, Se-Hoon; Kim, Dong-Wan; Lee, Yu Jeung Supportive Care in Cancer, Vol.25 No.2, pp.429-437	DOI
2017-03	Prognostic Impact of Newly Proposed M Descriptors in TNM Classification of Non-Small Cell Lung Cancer Shin, Junghoon; Keam, Bhumsuk; Kim, Miso; Park, Young Sik; Kim, Tae Min; Kim, Dong-Wan; Kim, Young Whan; Heo, Dae Seog Journal of Thoracic Oncology, Vol.12 No.3, pp.520-528	DOI
2017-04	Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component Yang, James Chih-Hsin; Ahn, Myung-Ju; Kim, Dong-Wan; Ramalingam, Suresh S.; Sequist, Lecia V.; Su, Wu-Chou; Kim, Sang-We; Kim, Joo-Hang; Planchard, David; Felip, Enriqueta; Blackhall, Fiona; Haggstrom, Daniel; Yoh, Kiyotaka; Novello, Silvia; Gold, Kathryn; Hirashima, Tomonori; Lin, Chia-Chi; Mann, Helen; Cantarini, Mireille; Ghiorghiu, Serban; Janne, Pasi A. Journal of Clinical Oncology, Vol.35 No.12, pp.1288-1296	DOI
2017-04	MET exon 14 skipping mutation in triple-negative pulmonary adenocarcinomas and pleomorphic carcinomas: An analysis of intratumoral MET status heterogeneity and clinicopathological characteristics Kwon, Dohee; Koh, Jaemoon; Kim, Sehui; Go, Heounjeong; Kim, Young A; Keam, Bhumsuk; Kim, Tae Min; Kim, Dong-Wan; Jeon, Yoon Kyung; Chung, Doo Hyun Lung Cancer, Vol.106, pp.131-137	DOI
2017-04	Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042) Kim, Dong-Wan; Garon, Edward B.; Jatoi, Aminah; Keefe, Dorothy M.; Lacouture, Mario E.; Sonis, Stephen; Gernhardt, Diana; Wang, Tao; Giri, Nagdeep; Doherty, Jim P.; Nadanaciva, Sashi; O'Connell, Joseph; Sbar, Eric; Cho, Byoung Chul Lung Cancer, Vol.106, pp.76-82	DOI
2017-04	Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer Kim, Miso; Keam, Bhumsuk; Kim, Tae-Min; Kim, Hoon-Gu; Kim, Jin-Soo; Lee, Sung Sook; Shin, Seong Hoon; Kim, Min Kyoung; Park, Keon Uk; Kim, Dong-Wan; Yun, Hwan Jung; Lee, Jong Seok; Heo, Dae Seog Cancer Research and Treatment, Vol.49 No.2, pp.416-422	view file DOI
2017-05	Superior Treatment Response and In-field Tumor Control in Epidermal Growth Factor Receptor-mutant Genotype of Stage III Nonsquamous Non-Small cell Lung Cancer Undergoing Definitive Concurrent Chemoradiotherapy Lim, Yu Jin; Chang, Ji Hyun; Kim, Hak-Jae; Keam, Bhumsuk; Kim, Tae Min; Kim, Dong-Wan; Paeng, Jin Chul; Kang, Keon Wook; Chung, June-Key; Jeon, Yoon Kyung; Chung, Doo Hyun; Wu, Hong-Gyun Clinical Lung Cancer, Vol.18 No.3, pp.e169-e178	DOI
2017-05	Novel JAK3-Activating Mutations in Extranodal NK/T-Cell Lymphoma, Nasal Type Sim, Sung Hoon; Kim, Soyeon; Kim, Tae Min; Jeon, Yoon Kyung; Nam, Soo Jeong; Ahn, Yong-Oon; Keam, Bhumsuk; Park, Hyun Ho; Kim, Dong-Wan; Kim, Chul Woo; Heo, Dae Seog American Journal of Pathology, Vol.187 No.5, pp.980-986	DOI
2017-05	KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer Park, Sehhoon; Kim, Ji-Yeon; Lee, Se-Hoon; Suh, Beomseok; Keam, Bhumsuk; Kim, Tae Min; Kim, Dong-Wan; Heo, Dae Seog The Korean Journal of Internal Medicine, Vol.32 No.3, pp.514-522	view file DOI
2017-06	Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma Ock, Chan-Young; Kim, Sehui; Keam, Bhumsuk; Kim, Soyeon; Ahn, Yong-Oon; Chung, Eun-Jae; Kim, Jin-Ho; Kim, Tae Min; Kwon, Seong Keun; Jeon, Yoon Kyung; Jung, Kyeong Chun; Kim, Dong-Wan; Wu, Hong-Gyun; Sung, Myung Whun; Heo, Dae Seog Oncotarget, Vol.8 No.58, pp.97920-97927	view file DOI
2017-08	Scientific Advances in Thoracic Oncology 2016 Soo, Ross A.; Stone, Emily C. A.; Cummings, K. Michael; Jett, James R.; Field, John K.; Groen, Harry J. M.; Mulshine, James L.; Yatabe, Yasushi; Bubendorf, Lukas; Dacic, Sanja; Rami-Porta, Ramon; Detterbeck, Frank C.; Lim, Eric; Asamura, Hisao; Donington, Jessica; Wakelee, Heather A.; Wu, Yi-Long; Higgins, Kristin; Senan, Suresh; Solomon, Benjamin; Kim, Dong-Wan; Johnson, Melissa; Yang, James C. H.; Sequist, Lecia V.; Shaw, Alice T.; Ahn, Myung-Ju; Costa, Daniel B.; Patel, Jyoti D.; Horn, Leora; Gettinger, Scott; Peters, Solange; Wynes, Murry W.; Faivre-Finn, Corinne; Rudin, Charles M.; Tsao, Anne; Baas, Paul; Kelly, Ronan J.; Leighl, Natasha B.; Scagliotti, Giorgio V.; Gandara, David R.; Hirsch, Fred R.; Spigel, David R. Journal of Thoracic Oncology, Vol.12 No.8, pp.1183-1209	DOI
2017-08	Alectinib versus crizotinib in untreated ALK-positive non–small-cell lung cancer Peters, Solange; Camidge, D. Ross; Shaw, Alice T.; Gadgeel, Shirish; Ahn, Jin S.; Kim, Dong-Wan; Ou, Sai-Hong I.; Perol, Maurice; Dziadziuszko, Rafal; Rosell, Rafael; Zeaiter, Ali; Mitry, Emmanuel; Golding, Sophie; Balas, Bogdana; Noe, Johannes; Morcos, Peter N.; Mok, Tony New England Journal of Medicine, Vol.377 No.9, pp.829-838	DOI
2017-08	Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial Kim, Dong-Wan; Tiseo, Marcello; Ahn, Myung-Ju; Reckamp, Karen L.; Hansen, Karin Holmskov; Kim, Sang-We; Huber, Rudolf M.; West, Howard L.; Groen, Harry J. M.; Hochmair, Maximilian J.; Leighl, Natasha B.; Gettinger, Scott N.; Langer, Corey J.; Rodriguez, Luis G. Paz-Ares; Smit, Egbert F.; Kim, Edward S.; Reichmann, William; Haluska, Frank G.; Kerstein, David; Camidge, D. Ross Journal of Clinical Oncology, Vol.35 No.22, pp.2490-2498	DOI
2017-08	Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive nonsmall- cell lung cancer Blackhall, Fiona; Camidge, D. Ross; Shaw, Alice T.; Soria, Jean-Charles; Solomon, Benjamin J.; Mok, Tony; Hirsh, Vera; Jaenne, Pasi A.; Shi, Yuankai; Yang, Pan-Chyr; De Pas, Tommaso; Hida, Toyoaki; Carpeno, Javier De Castro; Lanzalone, Silvana; Polli, Anna; Iyer, Shrividya; Reisman, Arlene; Wilner, Keith D.; Kim, Dong-Wan Esmo Open, Vol.2 No.3, p. e000219	DOI
2017-09	ASCEND-8: A randomized phase 1 study of ceritinib, 450 mg or 600 mg, taken with a low-fat meal versus 750 mg in fasted state in patients with anaplastic lymphoma kinase (ALK)-rearranged metastatic non-small cell lung cancer (NSCLC) Cho, Byoung Chul; Kim, Dong-Wan; Bearz, Alessandra; Laurie, Scott A.; McKeage, Mark; Borra, Gloria; Park, Keunchil; Kim, Sang-We; Ghosn, Marwan; Ardizzoni, Andrea; Maiello, Evaristo; Greystoke, Alastair; Yu, Richard; Osborne, Karen; Gu, Wen; Scott, Jeffrey W.; Passos, Vanessa Q.; Lau, Yvonne Y.; Wrona, Anna Journal of Thoracic Oncology, Vol.12 No.9, pp.1357-1367	DOI
2017-09	Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria Gandhi, Leena; Ou, Sai-Hong Ignatius; Shaw, Alice T.; Barlesi, Fabrice; Dingemans, Anne-Marie C.; Kim, Dong-Wan; Camidge, D. Ross; Hughes, Brett G. M.; Yang, James C. -H.; de Castro, Javier; Crino, Lucio; Lena, Herve; Do, Pascal; Golding, Sophie; Bordogna, Walter; Zeaiter, Ali; Kotb, Ahmed; Gadgeel, Shirish European Journal of Cancer, Vol.82, pp.27-33	DOI
2017-09	Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas Lee, June-Koo; Lee, Junehawk; Kim, Sehui; Kim, Soyeon; Youk, Jeonghwan; Park, Seongyeol; An, Yohan; Keam, Bhumsuk; Kim, Dong-Wan; Heo, Dae Seog; Kim, Young Tae; Kim, Jin-Soo; Kim, Se Hyun; Lee, Jong Seok; Lee, Se-Hoon; Park, Keunchil; Ku, Ja-Lok; Jeon, Yoon Kyung; Chung, Doo Hyun; Park, Peter J.; Kim, Joon; Kim, Tae Min; Ju, Young Seok Journal of Clinical Oncology, Vol.35 No.26, pp.3065-3074	DOI
2017-10	Pooled systemic efficacy and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small cell lung cancer Yang, James Chih-Hsin; Ou, Sai-Hong Ignatius; De Petris, Luigi; Gadgeel, Shirish; Gandhi, Leena; Kim, Dong-Wan; Barlesi, Fabrice; Govindan, Ramaswamy; Dingemans, Anne-Marie C.; Crino, Lucio; Lena, Nerve; Popat, Sanjay; Ahn, Jin Seok; Dansin, Eric; Golding, Sophie; Bordogna, Walter; Batas, Bogdana; Morcos, Peter N.; Zeaiter, Ali; Shaw, Alice T. Journal of Thoracic Oncology, Vol.12 No.10, pp.1552-1560	DOI
2017-11	The prognostic value of CT radiomic features for patients with pulmonary adenocarcinoma treated with EGFR tyrosine kinase inhibitors Kim, Hyungjin; Park, Chang Min; Keam, Bhumsuk; Park, Sang Joon; Kim, Miso; Kim, Tae Min; Kim, Dong-Wan; Heo, Dae Seog; Goo, Jin Mo PLoS ONE, Vol.12 No.11, p. e0187500	view file DOI
2017-11	Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study Ahn, Myung-Ju; Kim, Dong-Wan; Cho, Byoung Chul; Kim, Sang-We; Lee, Jong Seok; Ahn, Jin-Seok; Kim, Tae Min; Lin, Chia-Chi; Kim, Hye Ryun; John, Thomas; Kao, Steven; Goldman, Jonathan W.; Su, Wu-Chou; Natale, Ronald; Rabbie, Sarit; Harrop, Bryony; Overend, Philip; Yang, Zhenfan; Yang, James Chih-Hsin The Lancet Respiratory Medicine, Vol.5 No.11, pp.891-902	DOI
2017-12	Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study Ott, Patrick A.; Elez, Elena; Hiret, Sandrine; Kim, Dong-Wan; Morosky, Anne; Saraf, Sanatan; Piperdi, Bilal; Mehnert, Janice M. Journal of Clinical Oncology, Vol.35 No.34, pp.3823-3829	DOI
2018-01	Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor Park, Sehhoon; Ha, Seunggyun; Lee, Se-Hoon; Paeng, Jin Chul; Keam, Bhumsuk; Kim, Tae Min; Kim, Dong-Wan; Heo, Dae Seog PLoS ONE, Vol.13 No.1, p. e0189766	view file DOI
2018-01	Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC Gadgeel, Shirish; Shaw, Alice T.; Barlesi, Fabrice; Crino, Lucio; Yang, James Chih-Hsin; Dingemans, Anne-Marie C.; Kim, Dong-Wan; de Marinis, Filippo; Schulz, Mathias; Liu, Shiyao; Gupta, Ravindra; Kotb, Ahmed; Ou, Sai-Hong Ignatius British Journal of Cancer, Vol.118 No.1, pp.38-42	DOI

1 2 3 4 5